📊 RSMDF Key Takeaways
Is Resmed Inc. (RSMDF) a Good Investment?
ResMed demonstrates exceptional fundamental strength with 26.9% net margins, robust 34% operating margins, and impressive free cash flow of $725.6M. The company exhibits financial fortress characteristics with minimal leverage (0.06x debt/equity), strong liquidity (3.06x current ratio), and 55.9x interest coverage, while simultaneously generating high-quality earnings with net income growing 37.2% YoY.
Why Buy Resmed Inc. Stock? RSMDF Key Strengths
- Exceptional profitability with 26.9% net margin and 34% operating margin among highest in medical devices
- Fortress balance sheet: minimal debt at 0.06x D/E ratio, $1.4B cash, and extraordinary 55.9x interest coverage
- Strong cash generation with $725.6M free cash flow and 26.3% FCF margin indicating high-quality earnings
- Operational leverage evident: net income growing 37.2% YoY on 9.8% revenue growth showing cost discipline and efficiency gains
- Excellent liquidity with 3.06x current ratio and 2.32x quick ratio providing significant financial flexibility
RSMDF Stock Risks: Resmed Inc. Investment Risks
- Net income acceleration (37.2%) significantly outpacing revenue growth (9.8%) requires verification of sustainability and potential one-time items
- Moderate ROE of 11.7% despite exceptional profitability suggests capital efficiency concerns or asset-heavy business model
- Medical device sector exposure to regulatory changes, reimbursement pressures, and competitive innovation threats
- Elevated insider trading activity (10 Form 4 filings in 90 days) warrants monitoring for directional signals
- Low capital expenditure ($71.5M on $2.8B revenue) may indicate underinvestment in future growth initiatives
Key Metrics to Watch
- Gross margin sustainability and trend to verify profitability is not artificially elevated
- Drivers behind net income outperformance vs revenue growth to assess one-time vs recurring benefits
- Operating expense ratios and headcount trends to validate operational leverage claim
- Free cash flow conversion and capital allocation priorities given strong cash generation
- Revenue growth trajectory and segment performance to confirm 9.8% growth is sustainable
Resmed Inc. (RSMDF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 26.3% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.06x current ratio provides a solid financial cushion.
RSMDF Profit Margin, ROE & Profitability Analysis
RSMDF vs Healthcare Sector: How Resmed Inc. Compares
How Resmed Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Resmed Inc. Stock Overvalued? RSMDF Valuation Analysis 2026
Based on fundamental analysis, Resmed Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Resmed Inc. Balance Sheet: RSMDF Debt, Cash & Liquidity
RSMDF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Resmed Inc.'s revenue has grown significantly by 61% over the 5-year period, indicating strong business expansion. The most recent EPS of $6.09 reflects profitable operations.
RSMDF Revenue Growth, EPS Growth & YoY Performance
RSMDF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $1.3B | $311.4M | $2.34 |
| Q1 2026 | $1.2B | $311.4M | $2.11 |
| Q3 2025 | $1.2B | $208.8M | $2.04 |
| Q2 2025 | $1.2B | $208.8M | $1.42 |
| Q1 2025 | $1.1B | $219.4M | $1.49 |
| Q3 2024 | $1.1B | $208.8M | $1.58 |
| Q2 2024 | $1.0B | $208.8M | $1.42 |
| Q1 2024 | $950.3M | $210.5M | $1.43 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Resmed Inc. Dividends, Buybacks & Capital Allocation
RSMDF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Resmed Inc. (CIK: 0000943819)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RSMDF
What is the AI rating for RSMDF?
Resmed Inc. (RSMDF) has an AI rating of STRONG BUY with 82% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RSMDF's key strengths?
Claude: Exceptional profitability with 26.9% net margin and 34% operating margin among highest in medical devices. Fortress balance sheet: minimal debt at 0.06x D/E ratio, $1.4B cash, and extraordinary 55.9x interest coverage.
What are the risks of investing in RSMDF?
Claude: Net income acceleration (37.2%) significantly outpacing revenue growth (9.8%) requires verification of sustainability and potential one-time items. Moderate ROE of 11.7% despite exceptional profitability suggests capital efficiency concerns or asset-heavy business model.
What is RSMDF's revenue and growth?
Resmed Inc. reported revenue of $2.8B.
Does RSMDF pay dividends?
Resmed Inc. pays dividends, with $175.3M distributed to shareholders in the trailing twelve months.
Where can I find RSMDF SEC filings?
Official SEC filings for Resmed Inc. (CIK: 0000943819) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RSMDF's EPS?
Resmed Inc. has a diluted EPS of $5.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RSMDF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Resmed Inc. has a STRONG BUY rating with 82% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is RSMDF stock overvalued or undervalued?
Valuation metrics for RSMDF: ROE of 11.7% (sector avg: 15%), net margin of 26.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RSMDF stock in 2026?
Our dual AI analysis gives Resmed Inc. a combined STRONG BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is RSMDF's free cash flow?
Resmed Inc.'s operating cash flow is $797.1M, with capital expenditures of $71.5M. FCF margin is 26.3%.
How does RSMDF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 26.9% (avg: 12%), ROE 11.7% (avg: 15%), current ratio 3.06 (avg: 2).